{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:50:25Z","timestamp":1760143825396,"version":"build-2065373602"},"reference-count":49,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: eBEACOPP is the most effective chemotherapy regimen for younger patients with early unfavorable (EU) and advanced-stage (AS) Hodgkin lymphoma (HL), albeit with significant toxicities. The 14-day\/cycle prednisone course contributes to side effects, including osteoarticular events like avascular bone necrosis (AVN). Our center has been using eBEACOPP since 2009 for AS and 2014 for EU patients. In 2016, we reduced prednisone treatment to 7\u201310 days to lessen AVN risk. We analyzed the effects of this approach. Materials and Methods: We retrospectively collected data on patients who received at least two cycles of eBEACOPP for first-line HL treatment. Results: A total of 162 patients (33 EU, 129 AS) were included. Their median age was 31 (range 19\u201359 years), and 88 were males. A total of 94 patients received full corticosteroid courses, and 68 received reduced corticosteroid courses. The overall response rate (ORR) was 98%. Different corticosteroid dosings had no significant effect on ORR, febrile neutropenia episodes, or hospital admissions. After a median follow-up (mFU) of 58 months, the 5yPFS for the entire cohort was 98% vs. 95% for the standard course vs. the short corticosteroids course, respectively (p = 0.37), while the 5yOS was 98% vs. 99% for the standard course vs. short corticosteroids course, respectively (p = 0.87). In AS patients intended to be treated with six eBEACOPP cycles, 5yPFS and 5yOS were 100% vs. 97% and 100% vs. 99% for standard vs. short corticosteroid courses, respectively (p = 0.56 and p = 0.17). In EU patients, 5yPFS was 97% (standard) vs. 95% (short) (p = 0.98) and 5yOS 100% vs. 93.3% (p = 0.87). Osteoarticular events were numerically lower in patients receiving the shorter prednisone course, both in the whole cohort and in the subgroup of patients treated with six cycles of eBEACOPP, but this difference failed to reach statistical significance. Conclusions: eBEACOPP provides excellent and durable first-line disease control. Shortening the corticosteroid course does not compromise efficacy, potentially reducing toxicity. However, longer follow-ups and larger studies are needed for confirmation.<\/jats:p>","DOI":"10.3390\/medicina60030430","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T08:03:47Z","timestamp":1709539427000},"page":"430","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP)"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5527-0647","authenticated-orcid":false,"given":"Ida","family":"Hude Dragi\u010devi\u0107","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, University Hospital Center Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Ba\u0161i\u0107-Kinda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, University Hospital Center Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Markoti\u0107","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital Mostar, Ulica Kralja Tvrtka bb, 88000 Mostar, Bosnia and Herzegovina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Mori\u0107-Peri\u0107","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, General Hospital Zadar, Bo\u017ee Peri\u010di\u0107a 5, 23000 Zadar, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dino","family":"Dujmovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, University Hospital Center Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Radman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, University Hospital Center Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Dreta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, University Hospital Center Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snje\u017eana","family":"Dotli\u0107","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cytology, University Hospital Center Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, \u0160alata 2b, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Ili\u0107","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cytology, University Hospital Center Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, \u0160alata 2b, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2840-5734","authenticated-orcid":false,"given":"Lea","family":"Galuni\u0107 Bili\u0107","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, University Hospital Center Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margareta","family":"Dobreni\u0107","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Radiation Protection, University Hospital Center Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Kralik","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospital Center Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Aurer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, University Hospital Center Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, \u0160alata 2b, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2006.07.0482","article-title":"Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin\u2019s Lymphoma: Final Results of the GHSG HD7 Trial","volume":"25","author":"Engert","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin\u2019s Disease","volume":"357","author":"Eghbali","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced Treatment Intensity in Patients with Early-Stage Hodgkin\u2019s Lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): A multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1200\/JCO.2010.30.9799","article-title":"Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP\/EBV\/CAD in patients with newly diagnosed advanced-stage Hodgkin\u2019s lymphoma: A study from the Intergruppo Italiano Linfomi","volume":"29","author":"Chisesi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin\u2019s Lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2015.62.4817","article-title":"Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi","volume":"34","author":"Merli","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin\u2019s Lymphoma When High-Dose Salvage Is Planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","article-title":"Eight Cycles of ABVD Versus Four Cycles of BEACOPP escalated Plus Four Cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score \u2265 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergro","volume":"34","author":"Carde","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdu189","article-title":"ABVD (8 cycles) versus BEACOPP (4 escalated cycles \u2265 4 baseline): Final results in stage III\u2013IV low-risk Hodgkin lymphoma (IPS 0\u20132) of the LYSA H34 randomized trial\u2020","volume":"25","author":"Mounier","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_12","first-page":"CD007941","article-title":"Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma","volume":"5","author":"Skoetz","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin\u2019s lymphoma: Final analysis of the German Hodgkin Study Group HD14 trial","volume":"30","author":"Plutschow","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2013-07-512657","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: A report from the German Hodgkin Study Group","volume":"11","author":"Eichenauer","year":"2014","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1002\/cam4.3298","article-title":"Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials","volume":"9","author":"Carde","year":"2020","journal-title":"Cancer Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after hodgkin lymphoma treatment 40-year disease risk","volume":"175","author":"Schaapveld","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin\u2019s disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Gerardi, C., Allocati, E., Minoia, C., Guarini, A., and Banzi, R. (2021). Long-term follow-up of classical hodgkin lymphoma and diffuse large B-cell lymphoma survivors: Aims and methodological approach for fondazione italiana linfomi systematic reviews. Cancers, 13.","DOI":"10.3390\/cancers13122976"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","article-title":"Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin study group HD13 to HD15 Trials","volume":"31","author":"Behringer","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/j.seminhematol.2016.05.008","article-title":"Hodgkin lymphoma: Late effects of treatment and guidelines for surveillance","volume":"53","author":"Ng","year":"2016","journal-title":"Semin. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis","volume":"13","author":"Leufkens","year":"2002","journal-title":"Osteoporos. Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ecl.2012.04.004","article-title":"Glucocorticoid-Induced Osteoporosis and Osteonecrosis","volume":"41","author":"Weinstein","year":"2012","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ofshenko, N., Bercovich, E., Mashiach, T., Weiler-Sagie, M., Militianu, D., and Dann, E.J. (2022). Reduction of the Vertebral Bone Mineral Density in Patients with Hodgkin Lymphoma Correlates with Their Age and the Treatment Regimen They Received. Cancers, 14.","DOI":"10.3390\/cancers14030495"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5371\/hp.2023.35.3.147","article-title":"Updating Osteonecrosis of the Femoral Head","volume":"35","author":"Ko","year":"2023","journal-title":"Hip. Pelvis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2257.1994.tb00381.x","article-title":"Osteonecrosis following treatment for Hodgkin\u2019s disease","volume":"16","author":"Ellis","year":"1994","journal-title":"Clin. Lab. Haematol."},{"key":"ref_27","first-page":"135","article-title":"Osteonecrosis as a complication of treating Hodgkin\u2019s lymphoma after BEACOPP chemotherapy","volume":"27","author":"Feltl","year":"2004","journal-title":"Oncology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ajh.22187","article-title":"A 10-year experience with treatment of high and standard risk Hodgkin disease: Six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved","volume":"87","author":"Dann","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/annonc\/mdr385","article-title":"Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: High cure rates but increased risk of aseptic osteonecrosis","volume":"23","author":"Fiskvik","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41375-018-0240-8","article-title":"Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: An analysis of the German Hodgkin Study Group (GHSG)","volume":"33","author":"Borchmann","year":"2018","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/imj.13653","article-title":"High incidence of aseptic hip necrosis in Hodgkin lymphoma patients treated with escalated BEACOPP receiving methylprednisolone","volume":"48","author":"Karlak","year":"2018","journal-title":"Intern. Med. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.1998.16.12.3810","article-title":"BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP\/ABVD in patients with advanced-stage Hodgkin\u2019s lymphoma: Interim report from a trial of the German Hodgkin\u2019s Lymphoma Study Group","volume":"16","author":"Diehl","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_33","unstructured":"(2022, October 16). Disease Stages and Risk Factors-GHSG-German Hodgkin Study Group. Available online: https:\/\/en.ghsg.org\/disease-stages."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_35","unstructured":"Cancer Institute, N. (2023, December 30). Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3325\/cmj.2016.57.77","article-title":"Survival analysis in clinical practice: Analyze your own data using an Excel workbook","volume":"57","year":"2016","journal-title":"Croat. Med. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): Final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3324\/haematol.2016.150656","article-title":"The emerging role of immune checkpoint inhibition in malignant lymphoma","volume":"102","author":"Hude","year":"2017","journal-title":"Haematologica"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.2012.47.9774","article-title":"Treatment-related mortality in patients with advanced-stage Hodgkin lymphoma: An analysis of the German Hodgkin Study Group","volume":"31","author":"Wongso","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","article-title":"Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin\u2019s lymphoma: Final analysis of the HD12 trial of the German Hodgkin Study Group","volume":"29","author":"Borchmann","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin\u2019s Lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2141.2010.08485.x","article-title":"Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses","volume":"152","author":"Gallamini","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study","volume":"127","author":"Barrington","year":"2016","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin\u2019s Lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000441962","article-title":"High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET\/CT Scan","volume":"135","author":"Kedmi","year":"2016","journal-title":"Acta Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41375-021-01386-z","article-title":"Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: Follow-up analysis of a randomized phase II study from the German Hodgkin Study Group","volume":"36","author":"Damaschin","year":"2022","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/hon.3196_LBA5","article-title":"Brecadd is non-inferior to ebeacopp in patients with advanced stage classical hodgkin lymphoma: Efficacy results of the ghsg phase iii hd21 trial","volume":"41","author":"Borchmann","year":"2023","journal-title":"Hematol. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/3\/430\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:08:29Z","timestamp":1760105309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/3\/430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,2]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["medicina60030430"],"URL":"https:\/\/doi.org\/10.3390\/medicina60030430","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2024,3,2]]}}}